Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvaliase in Adults with PKU (PRISM-2)
NCT01889862Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jul 2013
- Primary completion
- Jan 2016
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegvaliase in phenylketonuria (PKU) (4 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: Change From Baseline in the Blood Plasma Phenylalanine Concentration at 8 weeks. Started Jul 2013; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT01889862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889862.